Search
SF Healthcare Week: CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year
She walks us through LB-102, a methylated derivative of amisulpride, a therapy that has a history of success in Europe. Plus, her thoughts on the obesity market (she was CEO of Carmot Therapeutics at the time of its acquisition by Roche) and being a member of the Biotech CEO Sisterhood.
Jan 15
Biotech CEO Sisterhood: Heather Turner and Sheila Gujrathi discuss managing your board of directors effectively
Interviewed by Sisterhood editorial board member Sheila Gujrathi, former Carmot Therapeutics CEO and newly named CEO of LB Therapeutics...
Dec 19, 2024
.png){kind=logo}
